Trial
NCT04510285
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
—
Condition
Esophagogastric Tumors
Intervention
Trastuzumab
Why stopped
Lack of accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-01